Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes

Insight Molecular Diagnostics Inc.

2024-Q3 EPS reported -$2.36 revenue$395,000

Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.
Cash end Q3 $5.1M; raised $10.2M gross ($9.4M net) in Oct. private placement at $2.948/sh, 3.46M shares.
GraftAssure signed centers: ~9% German, ~2% US transplant volumes; on track for 20 centers by end of 2025.
FDA pre-sub (Q-sub) submitted for VitaGraft+ IVD; meeting scheduled early Dec.; six hospitals interested in clinical study.
Operating expenses (excl. non-cash) rose ~13% sequentially to $13.6M, driven by R&D and sales/marketing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.